Please ensure Javascript is enabled for purposes of website accessibility

3 Shares That Beat the FTSE Today

By Alan Oscroft – Dec 12, 2012 at 12:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

IDOX, Senior, and Scancell Holdings are all climbing.

LONDON -- The FTSE 100 (INDEX: ^FTSE) is still on the up this week, gaining 21 points today to reach 5,946 and improve on the nine-month high it reached yesterday. Mining shares have helped push the index upward today, with a number of share prices rising in line with commodities prices.

Individual constituents of the various FTSE indexes are doing well, too. Here are three whose prices are rising today.

IDOX (IDOX -0.61%)
Shares in software and services supplier IDOX gained another 4.7%, taking the price up about 90% over the past 12 months. Today's boost came from full-year results that saw adjusted pre-tax profits rise by 36% to 14.8 million pounds, based on a combination of "acquisitions, organic growth and international expansion."

Adjusted earnings per share came in 55% higher at 3.83 pence, and the full-year dividend was lifted by 13% to 0.675 pence per share -- only a 1.3% yield.

Senior (SNR -8.11%)
The share price recovery of engineer Senior continued today, with the price rising 3.3% to 208.5 pence after the firm's preclose trading update told us that profit expectations are in line with October's positive trading statement.

That suggests we'll be seeing earnings per share near the current 16.5 pence consensus, putting the shares on a price-to-earnings ratio of about 12. And we should see a dividend yield of about 2.2%. Senior shares are now up more than 25% over the past 12 months, despite a couple of dips along the way.

Scancell (SCLP)
Scancell Holdings shares continued the strong run that has seen the price rise sevenfold in the past 12 months, today putting on 0.2% to reach 49 pence. The developer of therapeutic cancer vaccines, which last week got a nice lift from favorable trial results, was further boosted today by the news that it has gained approval from the Gene Therapy Advisory Committee and the Healthcare products Regulatory Agency for a higher-dose trial of the same vaccine, SCIB1. The trial will commence in the new year.

Daily gains from shares can all play their part in making you your first million. But the real secret to becoming rich from shares is simple long-term investing in fundamentally sound companies and letting steady growth and dividends power your wealth upward. If you don't think making a million is feasible, read this free Motley Fool report and see if you change your mind. The report won't cost you a penny, so click here to have a copy delivered to your inbox while it's still available.

Alan does not own any shares mentioned in this article. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Scancell Holdings plc Stock Quote
Scancell Holdings plc
SCLP
$12.25 (%)
IDOX plc Stock Quote
IDOX plc
IDOX
$65.00 (-0.61%) $0.40
Senior plc Stock Quote
Senior plc
SNR
$111.00 (-8.11%) $-9.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.